A leading international securities law firm, Rosen Law Firm, has announced the filing of a class-action lawsuit against Checkpoint Therapeutics, Inc. The lawsuit alleges that the company made false and misleading statements to investors between March 10, 2021, and December 15, 2023. These statements allegedly concealed issues with the company’s manufacturing practices and its third-party contract manufacturing organization.
Investors who purchased Checkpoint securities during this period may be eligible for compensation without any out-of-pocket expenses or conditional payment arrangements. To join the class-action lawsuit or obtain more information, visit the Rosen Law Firm’s website or contact Phillip Kim via phone or email. The deadline for becoming the lead plaintiff in the lawsuit is June 4, 2024.
It is crucial for investors to choose a competent and reputable attorney to represent their interests. Many law firms lack the necessary experience, resources, or substantial professional networks to handle class-action securities lawsuits effectively. However, Rosen Law Firm has a proven track record of success and is ranked first by ISS Securities Class Action Services in 2017 for the number of settlements reached.
According to the lawsuit, Checkpoint Therapeutics, Inc. allegedly provided false and misleading information regarding its manufacturing practices, quality controls, and its leading product candidate, cosibelimab. These alleged misrepresentations reduced the likelihood of the company’s biologics license application being approved. As a result, investors suffered financial losses.
Investors who wish to join the class-action lawsuit can visit the Rosen Law Firm’s website or contact Phillip Kim for more information. It is important to note that no class has been certified yet, and investors are not represented by any advisory firm unless they enter into an agreement. In addition, investors have the choice to remain anonymous and take no action at this stage. The potential for future recovery is not dependent on being the lead plaintiff in the case.
For updates, follow the Rosen Law Firm on LinkedIn, Twitter, or Facebook. Please note that prior results do not guarantee a similar outcome.
For further information, please contact:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
The class-action lawsuit filed by the Rosen Law Firm against Checkpoint Therapeutics, Inc. highlights alleged false and misleading statements made by the company to investors between March 10, 2021, and December 15, 2023. These statements are said to have concealed issues with the company’s manufacturing practices and its third-party contract manufacturing organization.
Investors who purchased Checkpoint securities during this period may be eligible to receive compensation through the class-action lawsuit. The deadline for becoming the lead plaintiff in the lawsuit is June 4, 2024. To join the lawsuit or obtain more information, individuals can visit the Rosen Law Firm’s website or contact Phillip Kim, the attorney handling the case.
It is important for investors to choose a competent and reputable attorney to represent their interests in securities class-action lawsuits. Rosen Law Firm is recognized for its success and is ranked first by ISS Securities Class Action Services in 2017 for the number of settlements reached. This demonstrates the firm’s experience, resources, and professional network in handling such cases effectively.
The lawsuit alleges that Checkpoint Therapeutics, Inc. provided false and misleading information regarding its manufacturing practices, quality controls, and its product candidate, cosibelimab. These alleged misrepresentations had negative implications for the company’s biologics license application, potentially leading to financial losses for investors.
It should be noted that while the lawsuit has been filed, no class has been certified yet, and investors are not represented by any advisory firm unless they enter into an agreement. Investors also have the option to remain anonymous and take no action at this stage. The potential for future recovery is not dependent on being the lead plaintiff in the case.
For updates on the lawsuit, investors can follow the Rosen Law Firm on LinkedIn, Twitter, or Facebook. It is essential to remember that prior results do not guarantee a similar outcome in this case.
For further information or inquiries, individuals can contact Laurence Rosen, Esq. or Phillip Kim, Esq. at the Rosen Law Firm. The contact details are as follows:
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Fax: (212) 202-3827
Email: [email protected]
Website: www.rosenlegal.com
In discussing the current market trends related to Checkpoint Therapeutics, Inc. and class-action lawsuits in the securities industry, it is important to note that such lawsuits have become increasingly common in recent years. Investors are becoming more aware of their rights and are seeking compensation when they believe they have been misled or suffered financial losses due to corporate misconduct.
One key challenge associated with class-action lawsuits is the complexity and length of the legal process. These lawsuits can take months or even years to reach a settlement or judgment, requiring patience from investors. Additionally, the outcome of a class-action lawsuit is not guaranteed, and there is always the possibility of the case being dismissed or investors receiving a lower settlement than anticipated.
On the other hand, class-action lawsuits provide a collective approach for investors to seek compensation, potentially resulting in higher recoveries compared to individual lawsuits. They also serve as a deterrent for companies engaging in fraudulent or deceptive practices, as the financial impact of a class-action lawsuit can be significant.
It is advisable for investors to stay informed about securities class-action lawsuits, as they may impact the value of their investments. Keeping track of updates from reputable law firms, like the Rosen Law Firm, can help investors make informed decisions and take appropriate action if necessary.
For more information on class-action lawsuits and the securities industry, investors can visit reputable sources such as the Securities and Exchange Commission (SEC) website at www.sec.gov or the Financial Industry Regulatory Authority (FINRA) website at www.finra.org. These organizations provide valuable resources and guidance to investors dealing with securities-related legal matters.